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ABSTRACT 
 
Nanoparticles show an exciting opportunity within the medical field, such as in diagnostics 
or therapeutics, due to their capacity to be surface modified and loaded with dyes and 
drugs. Current clinical applications of nanoparticles include localisation in tumour cells for 
cancer therapy, delivery of nucleic acids and viral therapies such as HIV vaccination. An 
exciting area of nanomedicine is using nanotechnology to target inflammatory and chronic 
diseases that involve the generation of reactive oxygen species (ROS). Cerium provides 
excellent anti-ROS properties and its effect as a nanoparticle needs to be established. 
 
The clinical application of nanoparticles often requires an entry point, one of which is 
intravenously done. Once injected into the bloodstream, the endothelial cells that line the 
blood vessel are one of the first sites of exposure, and because endothelial cells are 
important modulators of vascular function, the influence of silica and ceria-coated silica 
nanoparticle uptake on vasodilation and cerium’s anti-ROS properties effect on 
vasodilation, remains unclear.The aim of the present study was to investigate the influence 
of silica and ceria-coated silica nanoparticles on vascular function of mouse aortic vessels, 
ex vivo. 
 
Silica, ceria and ceria-coated silica nanoparticles were successfully synthesised and their 
physicochemical characterisation determined. Their effect on constrictor, and both 
endothelial dependent and independent dilator responses were assessed, using the organ 
bath technique and evaluation of uptake was also conducted using TEM.  
 
The present study demonstrates two important findings. Firstly, that ceria-coated silica 
nanoparticles have an improved endothelial-dependent dilatory effect on young mouse 
aorta, whereas silica nanoparticles alone (C3) showed no detrimental effect on both 
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endothelial-dependent and -independent dilation. Secondly, that ceria-coated silica 
nanoparticles did not improve dilation in aged aortic vessels, and silica nanoparticles (C3) 
did not show to have a detrimental effect on dilation, since the dilator component in aged 
vessels was found to be similar to that in young vessels. 
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1. Introduction 
 
1.1 Structure and Function of the Vasculature 
 
Blood vessels are made up of three layers: tunica intima, tunica media and tunica 
adventitia.The tunica intima comprises of the endothelial basement membrane and the 
endothelial cells that lie on it. The tunica media comprises of smooth muscle cells that allow 
for constriction of the vessel and the tunica adventitia comprises of connective tissue. These 
layers can be seen in Figure 1. 
 
Although the smooth muscle cells are responsible for the constriction of the vessel, 
endothelial cells themselves can also modulate vessel diameter by releasing a variety of 
mediators. Of those mediators, nitric oxide (NO), prostacyclin, and endothelial-dependent 
hyperpolarising factors (EDHFs). Some mediators can induce constriction of the vessel, such 
as endothelin. These mediators are highly regulated to ensure adequate blood flow and 
perfusion in the body. As the body ages, there can be an imbalance of these mediators 
being released which leads to ‘endothelial dysfunction’. This imbalance can also be seen in 
the early stages of cardiovascular disease. 
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Figure 1 A diagram depicting the structure of (a) an artery (b) a vein and (c) a sample from human tissue 
showing a cross section of an artery and a vein. Image taken from (OpenStax College 2014) 
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1.2Mitochondrial/Free-Radical Theory of Ageing 
 
Due to medical advancements, improved sanitation and better personal care, there is an 
ever-increasing ageing population. Whilst ageing might not necessarily be synonymous with 
disease, it is thought to be a risk factor or associated indirectly to risk factors that contribute 
to disease (Lakatta and Levy 2003). 
 
There are currently a number of theories that try to explain why the ageing process occurs 
and what mechanisms lead to it, including the mitochondrial/free-radical theory of ageing. 
During normal respiration in the cell, the mitochondria is the location for the electron 
transport chain in which oxygen is converted into water which produces energy(Judge, Jang 
et al. 2005). This process, however, is not one hundred percent efficient as a small percent 
of the oxygen ends up being converted to reactive oxygen species (ROS) which are unstable 
and have unpaired electrons. These include peroxides (H2O2), superoxide (O2-), hydroxyl 
radical (OH-), and singlet oxygen (O2). These then are able to attach onto lipids, proteins 
and nucleic acids and alter their structure or composition. They also affect the 
mitochondrial DNA (mtDNA) that produce polypeptides which enable the electron 
transport chain to work efficiently. As these polypeptides get damaged, it spawns a 
negative cycle of more ROS being produced which in turn damage the polypeptides further. 
This leads to a decline in energy available and increases the amount of ROS produced. This 
decline in energy and the increased in ROS production is what is considered the cause of 
ageing and ageing-related diseases(Bratic and Larsson 2013). 
 
1.2 ROS and Cardiovascular Disease 
 
Ageing has been considered a risk factor for cardiovascular diseases amongst others, such 
as sedentary lifestyle, diet, and genetics(Spiteller 2001).Cardiovascular diseases are 
responsible for the most deaths worldwide and involve changes in the vasculature which 
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lead to a decline in function. These changes include calcification, atherosclerosis and, 
endothelial dysfunction(Kovacic, Moreno et al. 2011). Nitric oxide (NO), a potent 
vasodilator, is involved in the regulation of vascular tone and is released continuously by 
endothelial cells via the conversion of arginine to citrulline(Tousoulis 2012). ROS leads to a 
reduction in NO levels which ultimately lead to a reduction in  endothelial cell mediated 
vasodilation(van der Loo, Labugger et al. 2000) and leads to endothelium dysfunction. ROS 
also causes upregulation of the protein complex, nuclear factor kappaB (NF-κB) causing it 
to shift the vasculature to a more pro-thrombotic state (Donato, et al. 2007; Kollander, et 
al. 2010) which can contribute to risk of cardiovascular disease. Currently, most of the 
treatment options for ROS are nutritional supplementation of known antioxidants such as 
beta-carotene and vitamin E which are thought to reduce ROS levels. They do not reflect 
the same result in clinical trials (Vivekananthan, Penn et al. 2003) and therefore there is a 
need for better substances with antioxidant properties. 
 
Because ROS contain unpaired electrons, which make them unstable and highly reactive, 
current treatment revolves around antioxidants, and other substances, and their ability to 
neutralise and counteract against these unpaired electrons, effectively removing their 
ability to cause damage and bind to other molecules as efficiently. 
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1.3 ROS Treatments: Nutritional Supplementation 
 
Nutritional supplementation of known antioxidants have been investigated on their effect 
on ROS levels. Vitamin E has been shown to have antioxidant like properties due to their 
scavenging ability of singlet oxygen (Lee, Koo et al. 2004) although it is mainly involved in 
protecting against lipid peroxidation (Pryor 2000). It works along with ascorbic acid (vitamin 
C) to maintain recyclability (Kojo 2004).  It has been shown to be protective against heart 
disease and cancer (Meydani 2000). A study by(Yatin, Varadarajan et al. 2000) found that 
when rats were supplemented with vitamin E, it prevented the increase in ROS which was 
induced chemically. Vitamin C has been found to be an important antioxidant, with its 
ability to donate electrons and stabilising ROS. Supplementation of vitamin C has been 
shown to prevent heart disease, various cancers and protect against oxidative stress 
induced by smoking (Lee, Koo et al. 2004). Carotenoids have been found to have 
antioxidant properties as they donate electrons to ROS, however some of the trials 
conducted have shown it to be ineffective and may even detrimental to lowering ROS. 
Other suggestions have included, plant sterols (De Jong, Plat et al. 2007), however, they did 
not affect oxidative stress; grape polyphenols including resveratrol, flavans, and 
anthocyanins were found to decrease whole-body levels of oxidative stress in pre- and 
post-menopausal women (Zern, Wood et al. 2005); green tea polyphenols were found to 
protect human skin that was subjected to ultraviolet radiation-induced oxidative stress 
(Katiyar, Perez et al. 2000); alpha-Lipoic acid was found to protect against insulin resistance 
that was induced by oxidative stress (Maddux, See et al. 2001). There have been numerous 
human clinical trials investigating various antioxidants, such as vitamin E and beta-
carotene, and their effectiveness in treating cardiovascular disease, however, these trials 
have largely been unsuccessful (Vivekananthan, Penn et al. 2003) and more research is 
needed to evaluate other antioxidants for treatment of oxidative stress. 
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1.3.1 ROS Treatments: Pharmaceutical Treatment 
 
Pharmaceutical treatments have also surfaced that have been investigated for their effect 
on ROS levels. It is thought that the cardiovascular drugs prescribed owe their effectiveness 
to their indirect antioxidant properties (Weseler and Bast 2010) for example angiotensin-
converting enzyme (ACE) inhibitors have been shown to have antioxidant activity (Bartosz, 
Kedziora et al. 1997). A study by(Pashkow, Watumull et al. 2008) proposed a novel 
molecule for treatment of oxidative stress, named astaxanthin, which was found to have 
antioxidant properties and looked promising as a candidate for cardiovascular oxidative 
stress. Other newly designed pharmaceutical aids that have antioxidant properties have 
been produced that mimic the structure of naturally occurring antioxidants (Weseler and 
Bast 2010). 
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1.4. Current clinical applications of nanoparticles 
 
Nanoparticles have many potential benefits to medicine and current clinical applications 
include, diagnosis and treatment of cancer using quantum dots or nanoparticles made from 
dyes (Radenkovic, et al. 2016; Patra, 2016). Another area using nanoparticles is for the 
delivery of nucleic acids for treatment of genetic or regenerative diseases (Cheng and Lee. 
2016; Chen, et al. 2016). Nanoparticles can also be used for the vaccination of certain 
viruses, including HIV (Glass, et al. 2016). 
 
1.5. Nanoparticles and their potential role in ROS treatment 
 
Because ROS is implicated in many diseases and in ageing, there is a need for an effective 
treatment option that is able to neutralise ROS whilst maintaining minimal side effects. One 
of these options involves the use of nanoparticles which have antioxidant capabilities. 
 
Nanoparticles, as defined by the British Standards Institution, are particles with two or more 
dimensions in the nanoscale, between 1 and 100nm (BSI 2011). At this scale, nanoparticles 
exhibit different properties compared to their corresponding bulk materials. These 
properties include having a high surface area to volume ratio, unique quantum properties, 
as well as the ability to be modified with other molecules and materials. It is because of these 
properties that they have been considered in many different fields including in medicine. 
Nanoparticles have been considered for biomedical applications due to their small size, so 
that they are able to be taken up by cells. Nanoparticles have the ability to be modified, 
which can be used in targeted drug delivery. By targeting certain marker molecules, it can 
also be used to help identify levels of pathogens, or levels of genes, protein or metabolites 
in a sample (Baptista, Doria et al. 2011). Nanoparticles have also been considered for 
therapeutics, especially for cancer therapy (Alexis, Pridgen et al. 2009), and wound healing 
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(Krausz, Adler et al. 2015). There are some considerations for the material used to make the 
nanoparticles. It can be that the material itself possesses properties that can be biologically 
relevant, or that the material can be used to made to be mesoporous and allow for 
encapsulation of drugs or other molecules.  
1.6Nanoparticles and their effect on vasculature 
 
Nanoparticles used in clinical applications are often administered intravenously and 
therefore the effects on the vasculature need to be established so that the endothelial cell 
function is not compromised. Studies have looked at various types of nanoparticles and 
their effect on vascular function. A study by Gojova, et al. (2007) looked at different types 
of nanoparticles (iron oxide, yttrium oxide, and zinc oxide) and found that yttrium oxide 
and zinc oxide nanoparticles elicited an inflammatory response in human aortic endothelial 
cells following short-term exposure. A research report written for the Health Effects 
Institute (Boston, Massachusetts, USA) by Kennedy, et al. (2009) reviewed the effects of 
various nanoparticles (cerium, iron, zinc, and yttrium oxide) on human aortic endothelial 
cells, looking at markers of inflammation and generation of ROS and oxidative stress. They 
found that the zinc oxide nanoparticles induced inflammation and oxidative stress, whereas 
yttrium oxide increased in some of the markers, and iron oxide and cerium oxide did not 
induce inflammation or oxidative stress. These differences can be pinned down to the 
physical and chemical properties of the nanoparticles. A study by Farooq, et al. (2014) 
found that silica nanoparticles, after incubation, attenuated endothelial dependent 
vasodilator responses in rats and subsequent incubation in cerium oxide nanoparticles 
restored this attenuation. 
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1.7Ceria Nanoparticles and their role in ROS treatment 
1.7.1. Antioxidant property of cerium 
 
Cerium is the most abundant metal in the rare metal group named lanthanides(Hedrick 
2004). Cerium oxide have the ability to switch between its two oxidation states, 3+ and 4+, 
which gives it redox properties. Although the bulk material has these properties that are 
attractive to be used as an antioxidant, it is biologically more applicable to produce cerium 
oxide nanoparticles instead. 
 
1.7.2. Ceria nanoparticles and their effects on vascular and physiological function 
 
Ceria nanoparticles mimic superoxide dismutase and are a possible therapeutic option for 
ROS-related conditions. A recent study (Farooq, Mohamed et al. 2014)investigated vascular 
dilatory responses after incubation with nanoparticles and found that the attenuated 
dilation after treatment with silica nanoparticles, was partially restored after coating 
nanoparticles in ceria. From this, it was suggested that ceria nanoparticles could be used as 
a therapeutic option for the treatment of impaired vascular responses. 
 
Ceria nanoparticles have been found to have beneficial effects on physiological systems.A 
study (Kolattukudy, Quach et al. 1998) injected ceria nanoparticles into transgenic mice 
which expressed the monocyte chemo-attractant protein-1 (MCP-1) which, in control mice, 
induced myocardial inflammation and caused ischemic cardiomyopathy. It was found that 
mice that were injected with ceria nanoparticles did not exhibit as many clinical symptoms 
or were much milder than the controls. A study (Rzigalinski, Meehan et al. 2006) used 
Drosophilia as an animal model and found that consumption of ceria nanoparticles lead to 
an increased lifespan when compared to the controls, which was incidently similar to the 
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findings when Drosophilia is genetically altered to over-express SOD, it is found to increase 
lifespan by 30%. Ceria nanoparticles have been found to be biocompatible and not exert 
any toxic effects. Histology alterations were not seen, 30 days after nanoparticles were 
administered (Hirst, Karakoti et al. 2009) and there was no increased number of deaths 
after nanoparticle administration compared to controls, within 9 weeks (Xia, Kovochich et 
al. 2008). Ceria nanoparticles have been considered for use as a drug delivery system. The 
nanoparticles were responsive to increased reactive oxygen species and was shown to have 
a significant effect on drug loading for treating cancer (Muhammad, Wang et al. 2014). 
Ceria nanoparticles have been found to enhance radiotherapy treatment in cancer cells, by 
causing arresting cell cycle at the G2/M stage, inducing autophagy and increasing rate of 
cell death, when compared to radiation alone. It was interesting to note that ceria 
nanoparticles, alone, were not toxic to the cancer cells. These findings have clinical impact 
as ceria nanoparticles can increase sensitivity of cancer cells to radiation and may be used 
in conjunction with radiotherapy (Chen, Zhang et al. 2015).  
1.7.4. Ceria nanoparticles and their effects on cellular function  
 
Ceria (CeO2) nanoparticles have been of particular interest in regards to vascular disorders 
due to their antioxidant properties (Heckert, Karakoti et al. 2008). The free radical 
scavenging ability of ceria may be  due to the ratio of Ce3+/Ce4+ ions rather than the oxygen 
vacancies present. A high Ce3+ concentration is also favoured due to its enhanced 
superoxide dismutase (SOD) mimetic activity when compared to Ce4+(Karakoti et al. 2008). 
Whereas a lot of the literature supports the fact that a high Ce3+/Ce4+ ratio is necessary for 
its superoxide dismutase scavenging effects, a recent publication has found that there is an 
inhibition of these effects when ceria nanoparticles are in the presence of phosphate ions, 
as they interfere with the Ce3+ sites of the nanoparticles (McCormack, Mendez et al. 2014). 
Ceria nanoparticles have also been demonstrated to enhance cyto-protection of beta cells 
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from exposure to superoxide (Weaver and Stabler 2015). However, the group found that 
uptake of the ceria nanoparticles did cause cytotoxicity. This lead to them to produce a 
hydrogel containing ceria nanoparticles which provided the cyto-protection without the 
uptake and cytotoxicity, even when high concentrations of ceria nanoparticles were used. 
Ceria nanoparticles have been investigated in the treatment of age-related male infertility. 
Using rats as an animal model, ceria nanoparticles have been found to reduce ROS, 
increase catalase and SOD activity as well as improve sperm count and other parameters 
(Kobyliak, Falalyeyeva et al. 2015). Ceria nanoparticles have been found to exhibit 
antioxidant properties that provide protection in neurons from rat spinal cords whilst being 
biologically compatible as well as regenerative (Das, Patil et al. 2007). Ceria nanoparticles 
were found to be deposited in tissues in in vivo studies and reduced oxidative stress to the 
same level as a common therapeutic used to lower oxidative stress (Hirst, Karakoti et al. 
2013). A study (Kim, Kim et al. 2012) found that ceria nanoparticles were able to reduce 
ischemic brain damage as well as targeting damaged areas specifically. A study (Niu, Azfer 
et al. 2007) found that ceria nanoparticles prevented the progression of cardiac dysfunction 
by lowering oxidative stress and inflammation in mice. Ceria nanoparticles were also been 
investigated for the treatment of neurodegenerative diseases such as Parkinson’s disease. 
Ceria nanoparticles were able to reduce oxidative stress in PC12 cells that had been 
induced using manganese chloride, instead of the more commonly used hydrogen 
peroxide. Ceria nanoparticles were found to have a protective role and have potential for 
therapeutic use in Parkinson-like diseases (Pinna, Malfatti et al. 2015). 
In order to functionalise ceria nanoparticles, anchors may be needed to allow for molecules 
to bind to them. (Yang, Luo et al. 2014) studied the effectiveness of alendronate as an 
anchor, as it was found to have a high binding affinity to ceria nanoparticles and did not 
hinder ceria’s activity. It was also found to improve stability and reduce cytotoxicity. In a 
recent study, ceria nanoparticles have been coated with polyethylene glycol (PEG), using 
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alendronate as an anchor (Li, Yang et al. 2015). These nanoparticles were found to be more 
stable than naked ceria nanoparticles and were found to be more effective at protecting 
human hepatocytes from damage induced by gamma-radiation. The group also found that 
the PEGylated ceria nanoparticles contributed to an increase in SOD expression, which aids 
in the protection against ROS. Ceria nanoparticles were also investigated in its effect on the 
nuclear factor erythroid-2 (Nrf-2)/hemoxygenase-1 (HO-1) pathway which is implicated 
when there is oxidative stress from D-galactoseamine and lipopolysaccharide-induced 
hepatotoxicity. The ceria nanoparticles have been found to decrease translocation of Nrf-2, 
which brings about an antioxidative effect demonstrated by the increased levels of SOD 
and catalase (Hashem, Rashd et al. 2015). Dextran is another biocompatible polymer that 
can be used to coat ceria nanoparticles without inhibiting its antioxidant effect. They have 
been found to be cytotoxic to osteosarcoma cells, although a high concentration was 
needed, 250µg/mL, in order for the bone cancer cells to be killed. It is suggested that the 
dextran coating may play a role in ceria’s antioxidant/oxidant properties and its oxidant 
properties may be triggered due to the tumour microenvironment allowing for tumour 
selectivity (Yazici, Alpaslan et al. 2015). 
 
Ceria nanoparticles have been investigated in cellular studies. Ceria nanoparticles have 
been found to prevent oxidative stress in human umbilical vein endothelial cells by 
counteracting ROS using hydrogen peroxide. There was also a reduction in apoptosis and 
necrosis seen after uptake of nanoparticles. The mechanisms of uptake were investigated 
and it was found that the nanoparticles were taken up by endocytosis mediated by 
caveolae and clatharin, and were found throughout the cytoplasm (Chen, Hou et al. 2013). 
Ceria nanoparticles and mechanisms of exocytosis were also investigated in human 
microvascular endothelial cells and it was found that after uptake, nanoparticles that 
accumulate in the vesicles of the cell are emptied and it is thought that this process would 
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protect endothelial cells from accumulation of nanoparticles and its possible adverse 
effects (Strobel, Oehring et al. 2015). 
 
1.7.6. Conclusion 
 
As ceria nanoparticles have been investigated for its antioxidant ability, there is a question 
as to whether ceria nanoparticles can improve vascular function that may have been 
compromised during ageing, without any other symptoms of disease. 
1.8 Silica nanoparticles and their effect on vasculature 
 
Silica nanoparticles have also been investigated for many uses within medicine. The 
production of mesoporous (containing many pores) silica nanoparticles allows it to hold and 
deliver drugs as well as dyes for diagnostics (Tang, et al. 2012). 
With so many studies looking at the biomedical applications of these nanoparticles, more 
work is needed to assess their effect on the physiological system, including the vascular 
system. A study by Liu, et al. (2010) found that expose to silica nanoparticles in human 
umbilical cord vein endothelial cells resulted in the production of intracellular ROS which 
lead to endothelial dysfunction via oxidative stress. It has also been demonstrated, in 
previous work done by the group, that silica nanoparticlescan influence dilator responses in 
aortic vessels, depending on size, charge and dye encapsulation (Akbar et al, 2011; Farooq 
et al, 2013). A reduced dilator response from incubation with silica nanoparticles could then 
be partially restored when there was incubation with ceria-coated silica nanoparticles 
(Farooq et al, 2014). Hence, responses to ceria, silica, and ceria coated silica in aortic vessels 
from young and aged mice, will be examined in the present study. 
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1.9Methodologies for fabricating silica and ceria nanoparticles 
 
For silica nanoparticles, Stöber (Stöber, Fink et al. 1968) produced a method that was able 
to build up, through nucleation and other growth processes, a monodispersed colloid 
solution of spherical nanoparticles.  
For cerium oxide (ceria), there have been many different protocols used to produce them 
and no gold standard protocol has been found and adopted. So far, the different methods of 
synthesis include: hydrothermal (Masui, Hirai et al. 2002), precipitation (Chen and Chang 
2005), using supercritical fluid technology (Byrappa, Ohara et al. 2008), reverse micellar 
(Sathyamurthy, Leonard et al. 2005), and flame electrospray pyrolysis (Oh and Kim 2007). 
Due to the aggregated nature of ceria nanoparticles, coatings have been considered to result 
in a colloidal, well-dispersed solution. Coatings can electrostatically repel the nanoparticles 
(Mandzy, Grulke et al. 2005), or can be polymers (Corbierre, Cameron et al. 2001) to make 
sure the ceria doesn’t aggregate and get into contact with each other. Biocompatibility is 
another issue when thinking about adding extra materials onto the nanoparticle. If the 
coatings interfere with biological responses, it would be undesirable to continue working 
with them in the areas of nanomedicine.  
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1.10Nanoparticle Characterisation 
 
There are a range of techniques that are adopted to look at the properties of nanoparticles 
and determine their size, dispersion, aggregation and charge, as follows: 
 
1.10.1 Scanning electron microscopy 
 
This technique analyses size and morphology of nanoparticles by coating the sample with a 
thin layer of gold, which is then subjected to a beam of electrons that are scanned across 
the sample. When the electrons hit the sample, secondary electrons and scattered 
electrons are detected and are used to form an image. In Figure 2, the structure of the 
microscope can be seen. 
 
 
 
Figure 2 Image depicting the structure of a scanning electron microscope (taken from (Bradbury 2008)) 
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1.10.2 Transmission electron microscopy 
 
A transmission electron microscope works similarly to a light microscope except it uses 
electrons as the source instead of light. These electrons are beamed onto the sample and 
are scattered based in density of the sample. Those electrons that do not scatter end up 
passing through the sample and onto a fluorescent screen which then gives an image of the 
sample with different parts of the sample showing varying degrees of darkness depending 
on their density. This technique is used to analyse size and morphology of the 
nanoparticles. The structure of a transmission electron microscope can be seen in Figure 3. 
 
 
Figure 3 An image depicting the structure of a transmission electron microscope (taken from (Ford 2008)) 
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1.10.3 Dynamic light scattering 
 
This technique is also known as photon correlation spectroscopy and is based on the 
principle of Brownian motion, that is, the random movement of particles within a solution. 
The smaller the particle is, the faster the velocity in which they travelled. When using 
dynamic light scattering, a laser beam is focused through the sample. The particles within 
the sample diffract the laser beam and cause fluctuations in the scattering intensity, which 
correlates to the hydrodynamic diameter of the particle. The hydrodynamic diameter 
includes the diameter of the particle plus an electric dipole layer that forms from the 
solvent. This technique is used to analyse hydrodynamic diameter of nanoparticles in 
different solutions. 
 
1.10.4 Ultraviolet-visible spectroscopy 
 
This technique involves passing a spectrum of light, ranging from ultraviolet to visible, 
through a sample and measuring the absorbance of the light through the spectrum. The 
peaks of absorption can reveal information about the sample. In the case of cerium, the 
different absorption peaks allow the differentiation between cerium with a 3+ oxidation 
state, and cerium with a 4+ oxidation state. A peak at around 413nm indicates the presence 
of cerium 3+, and a peak at around 310nm indicates the presence of cerium 4+. 
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1.10.5 Zeta potential analysis 
 
This technique investigates the surface charge of nanoparticles when in solution. The 
particles, as mentioned before, have an electrical dipole layer caused by ions in the solution 
being attracted to the slight surface charge of the nanoparticle. The electrical potential on 
the boundary of this ion attraction, known as the electrical double layer, is known as the 
zeta potential. Zeta potential values of less than -25mV or greater than +25mV are 
considered to have high stability. Nanoparticles with zeta potential values within that range 
will be subjected to Van der Waals attraction with each other and cause aggregation over 
time (NanoComposix 2012). 
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1.11 Aims and Objectives 
 
The overall aim was to investigate the influence of silica, ceria, and ceria-coated silica 
nanoparticles on vascular function of mouse aortic vessels, ex vivo.  
 
The specific objectives were as follows: 
 
1. To fabricate and characterise silica, ceria, and ceria coated silica nanoparticles, 
using physicochemical characterisation techniques 
2. To determine the dilator response of aortic vessels in young and aged mice, ex vivo, 
using the organ bath technique 
3. To elucidate the influence of silica, and ceria coated silica nanoparticles on the 
functional (i.e. contractile and dilator) responses of isolated blood vessels from 
young and aged mice, ex vivo, using the organ bath technique. 
 
The Null Hypothesis is: 
1. There is no difference in the dilator response of aortic vessels between young and 
aged mice. 
2. Ceria-coated silica nanoparticles will have no influence on the dilator function of 
aged mouse aortic vessels. 
The Alternative hypothesis is: 
1. The dilator response of aortic vessels in aged mice is significantly reduced, in 
comparison to young mice 
2. Ceria-coated silica nanoparticles are able to restore dilator function in aortic 
vessels from aged mice. 
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2. Objective 1: Fabrication and Characterisation of 
Nanoparticles 
 
2.1. Preparation of Ceria and steric stabilised ceria Nanoparticles 
In this present study, there were many methods that were used to make ceria 
nanoparticles and there was a need to establish the best methodology to be used. Ceria 
nanoparticles (<25nm in size) were also purchased from Sigma Aldrich, UK. Table 1 below, 
provides an overview of the range of methods used.  
 
Table 1 Overview of methodologies used to produce ceria and steric stabilised ceria nanoparticles 
Ceria 
nanoparticle 
batch 
Reference Overview of methodology Modifications 
CeA (Farooq, 
Mohamed et al. 
2014) 
Cerium salt was dissolved in 
ethanol and was stirred into a 
sodium hydroxide solution 
(sodium hydroxide and ethanol). 
This was stirred and afterwards, 
hydrogen peroxide was added to 
form the precursor solution. 
Nitric acid and sodium hydroxide 
was added to the precursor and 
the product was centrifuged. 
N/A 
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CeB (Chen and Chang 
2005) 
Cerium salt solution was heated 
with ammonium hydroxide 
solution. This was stirred and 
centrifuged. 
PVP coating 
added post-
production 
Sigma Ceria Sigma Aldrich, UK No methodology provided with 
commercially bought ceria 
nanoparticles 
PVP coating 
added post-
production 
CeE (He, Wu et al. 
2012) 
Cerium salt, urea and PVP were 
dissolved into water. This was 
heated and ammonium 
hydroxide was added. This was 
stirred and centrifuged. 
PVP coating 
added during 
production 
CeF (Izu, Uchida et al. 
2011) 
PVP and cerium salt were 
dissolved into ethylene glycol. 
This was heated and stirred. The 
product was centrifuged. 
PVP coating 
added during 
production 
CeG Adapted from (He, 
Wu et al. 2012) 
Cerium salt, urea and dextran 
were dissolved into water. This 
was heated and ammonium 
hydroxide was added. This was 
stirred and centrifuged. 
Dextran 
coating added 
during 
production 
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CeA Method 
 
The method was taken from Farooq et al. (Farooq, Mohamed et al. 2014). Materials 
include: cerium nitrate hexahydrate (Sigma Aldrich, UK), industrial methylated spirit, 
sodium hydroxide, hydrogen peroxide (30%), distilled water and nitric acid (70%).  
 
One gram of cerium nitrate hexahydrate was stirred into 15.78 mL of industrial methylated 
spirit, and left stirring vigorously at 50C in a paraffin oil bath. In a separate vial, 1g of 
sodium hydroxide was stirred into 15.78 grams of industrial methylated spirit. The sodium 
hydroxide solution was added dropwise into the cerium nitrate solution and was stirred 
vigorously for twenty-four hours at 50C in a paraffin oil bath. Once cooled, 0.05mL of 
hydrogen peroxide was added and stirred for one hour. The precipitate formed was then 
centrifuged at 6000rpm for 20 minutes and the pellet was re-dispersed into 20mL distilled 
water. The solution’s pH was adjusted to pH 0.14 using 2mL of nitric acid. The solution was 
heated to 40C for 2 hours and left to cool afterwards at room temperature. This was the 
precursor solution. 
3mL of this solution was then dispersed into 30mL of distilled water whilst stirring. The 
mixture was then stirred vigorously for 30 minutes. The pH was adjusted to 9.1 using 5mL 
of sodium hydroxide solution (1M), which was added dropwise into the solution. It was 
then stirred for 3 hours and 35 minutes at 60C in a paraffin oil bath. The product was then 
centrifuged for 30 minutes and cleaned with water several times. 
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CeB Method 
 
The method was taken from Chen and Chang (Chen and Chang 2005). Materials include: 
0.2M cerium nitrate hexahydrate (Sigma Aldrich, UK) and 3M ammonium hydroxide. 
 
Fifty millilitres of cerium nitrate solution was heated to 70C in a paraffin oil bath and stirred 
vigorously. 25mL of the ammonium hydroxide solution was added to the cerium nitrate 
solution. This solution is left at 70C for 20 hours. The solution is then centrifuged at 
6000rpm for 20 minutes and cleaned with water several times. 
 
Commercially bought Ceria (Sigma Aldrich, UK) 
The method of production for these nanoparticles were not given. This product was 
purchased from Sigma Aldrich UK and the product code was ‘544841ALDRICH’. 
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2.2 Preparation of steric-stabilised Ceria Nanoparticles 
With aggregation being apparent in the ceria nanoparticles, it was decided that steric 
stabilisation was to be used in order to produce ceria nanoparticles without the 
aggregation and help form more individual nanoparticles. Two types of polymers were used 
to sterically stablise the nanoparticles, polyvinyl pyrrolidone (PVP) and dextran, which is 
polymerised glucose. 
 
Adding PVP onto nanoparticles 
CeB2PVP Method 
This method was adapted from Graf, et al. (Graf, Vossen et al. 2003). Materials included: 
ceria nanoparticles made from CeB method, PVP (molecular weight of 10,000 Daltons) and 
distilled water. 
 
6.9uL of CeB nanoparticles were resuspended in 40mL of distilled water to get a 
concentration of 1.44x1014 nanoparticles per mL. This solution was sonicated for 15 
minutes and then placed in a round bottomed flask and stirred using a magnetic flea stirrer. 
PVP solution was produced by dissolving 0.06g in 2.6mL of distilled water. This PVP solution 
was added into the ceria nanoparticle solution and was stirred for 24 hours. 
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CeSigPVP Method 
This method was adapted from Graf, et al. (Graf, Vossen et al. 2003). Materials included: 
ceria nanoparticles (purchased from Sigma Aldrich, UK), PVP (molecular weight of 10,000 
Daltons) and distilled water. 
 
0.01g of ceria nanoparticles were suspended in 25mL of distilled water to get a 
concentration of 1.72x1014 nanoparticles per mL. This solution was sonicated for 15 
minutes and then placed in a round bottomed flask and stirred using a magnetic flea stirrer. 
PVP solution was produced by dissolving 0.33g in 4mL of distilled water. This PVP solution 
was added into the ceria nanoparticle solution and was stirred for 24 hours. 
 
CeE Method 
 
The method was taken from He, et al. (He, Wu et al. 2012). Materials include: distilled 
water, cerium nitrate hexahydrate, urea, ammonium hydroxide (70%), and PVP (molecular 
weight of 10,000 Daltons) 
The cerium nitrate hexahydrate, urea and PVP were dissolved in the water. This was then 
heated to 70C in a paraffin oil bath for 1 hour, and stirred vigorously. Ammonium 
hydroxide was then added dropwise. Once a pale yellow precipitate had formed, the 
reaction was stopped and cooled to room temperature. It was then centrifuged at 6000rpm 
for 20 minutes and cleaned several times with water. 
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CeF Method 
 
The method was taken from Izu, et al. (Izu, Uchida et al. 2011). Materials included: ethylene 
glycol, PVP (molecular weight of 10,000 Daltons) and cerium nitrate hexahydrate. 
 
PVP (3.15g) and 7.82g of cerium nitrate hexahydrate were added to 30cm3 of ethylene 
glycol and stirred until dissolved. The solution was then transferred to a silicone oil bath at 
140C for 2 hours. It was then cooled to room temperature.  
 
Adding dextran onto nanoparticles 
CeG Method 
 
The method was adapted from He, et al.  (He, Wu et al. 2012), but used dextran to coat the 
nanoparticles instead of the PVP. Materials included: cerium hexahydrate, urea, distilled 
water, ammonium hydroxide and dextran (molecular weight of 500,000 Daltons). 
 
The cerium nitrate hexahydrate, urea and dextran were dissolved in the water. This was 
then heated to 70C in a paraffin oil bath for 1 hour, and stirred vigorously. Ammonium 
hydroxide was then added dropwise. Once a pale yellow precipitate had formed, the 
reaction was stopped and cooled to room temperature. It was then centrifuged at 6000rpm 
for 20 minutes and cleaned several times with water. 
 
  
32 
 
2.3Preparation of silica nanoparticles 
 
For the silica nanoparticles, there were two different types of methodologies used. SilA and 
SilB used the same method, but altered concentrations, to produce different sized 
nanoparticles, and SilC was done using a different method. Silica nanoparticles (A3) were 
also kindly provided by Ali Shukur. AN overview of the methods can be seen in Table 2. 
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Table 2Overview of the methodologies used to produce silica nanoparticles 
Silica 
nanoparticle 
batch 
Reference Overview of methodology Modifications 
SilA (Bagwe, Yang et al. 
2004) 
Triton X-100, cyclohexane, 
hexanol and water were stirred. 
Rhodamine dye was added, 
followed by TEOS and ammonium 
hydroxide. Product was retrieved 
by rotary evaporation and 
centrifuged. 
Rhodamine 
dye 
encapsulated 
SilB (Bagwe, Yang et al. 
2004) 
Details are the same as above 
using a different ratio of the 
materials. 
Rhodamine 
dye 
encapsulated 
SilC (Farooq, Mohamed 
et al. 2014) 
Ammonium hydroxide was added 
to ethanol and water. This 
solution was heated, and TEOS 
was added to it. This was then 
stirred and centrifuged. 
Ceria coating 
post-
production 
A3 (Stöber, Fink et al. 
1968, Ibrahim, 
Zikry et al. 2010) 
Ammonium hydroxide, ethanol, 
TEOS and double distilled water 
was stirred. Rhodmaine dye was 
added to this solution. This was 
then stirred and centrifuged. 
Rhodamine 
dye 
encapsulated 
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SilA and SilB Method 
 
This method was taken and modified from Bagwe, et al. (Bagwe, Yang et al. 2004). 
Materials included: rhodamine B isothiocyanate (RITC), (3-aminopropyl)triethoxysilane 
(APS), chloroform, Triton X-100, cyclohexane, hexanol, distilled water, tetraethyl 
orthosilicate (TEOS), and ammonium hydroxide. Quantities used for each chemical can be 
found in Table 3. 
 
The rhodamine dye was produced by pipetting 0.02mL of APS and 0.2mL of chloroform in a 
small vial. Weigh out 0.02g of RITC and transfer into the vial. Place a magnetic flea stirrer 
into the vial and leave to stir overnight at room temperature. 
 
Table 3 Quantities of materials needed to produce silica nanoparticles using reverse microemulsion 
Sample 
Name 
Rhodamine 
dye (μL) 
Triton 
X-100 
(mL) 
Cyclohexane 
(mL) 
Hexanol 
(mL) 
Distilled 
Water 
(mL) 
TEOS 
(mL) 
Ammonium 
hydroxide 
(mL) 
SilA 100 1.77 7.5 1.8 0.40 0.2 0.10 
SilB 100 7.10 3.0 7.2 2.25 0.4 0.24 
 
Using a glass Pasteur pipette take, Triton X-100, cyclohexane, hexanol and water were 
placed into a round bottomed flask and stirred for 15 minutes at room temperature using a 
magnetic flea stirrer. The rhodamine dye was slowly added in and the solution was stirred 
for an hour at room temperature. TEOS and ammonium hydroxide was added to the 
solution and it was stirred for 24 hours at room temperature.  
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Once the reaction had completed, products were recovered by rotary evaporation at 30C 
until there is little solvent left. The nanoparticles were isolated by acetone and centrifuged 
for 20 minutes at 6000rpm, and washed with ethanol and water several times. 
 
SilC Method 
 
The method was taken from Farooq, et al. (Farooq, Mohamed et al. 2014). Materials 
included: distilled water, ammonium hydroxide, industrial methylated spirit, TEOS. 
Ammonium hydroxide (6.53mL) was added to a solution containing 88.3mL of ethanol and 
1.91mL of water, which is heated in a silicone oil bath to 60C. Separately, a solution 
containing 2.27mL of TEOS and 2.23mL of ethanol was mixed. The TEOS solution was added 
drop-wise to the ammonium hydroxide solution and was stirred vigorously for 21 hours at 
60C. Once cooled, it was centrifuged at 6000rpm for 30 minutes and washed with ethanol 
and water several times. 
 
A3 Silica 
 
These nanoparticles were kindly provided by Ali Shukur, who had produced them, using the 
methodology outlined in (Stöber, Fink et al. 1968, Ibrahim, Zikry et al. 2010) with 
modifications outlined below. Materials included: double distilled water, ethanol, 
ammonium hydroxide, TEOS, RITC, and APS. 
 
Firstly, the rhodamine dye was produced by adding 40mg of RITC into 600µL of APS, and 
was stirred at room temperature using a magnetic flea stirrer. The reaction vessel was filled 
with nitrogen gas and mechanically stirred for 3 hours, in the absence of light. 
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In a separate vial, 4.89mL of ammonium hydroxide, 250mL of ethanol, 2.9775mL of double 
distilled water and 3.776g of TEOS solution were stirred using a magnetic flea stirrer for 15 
minutes at room temperature. 50µL of the rhodamine dye was added, and this combined 
solution was stirred for 3 hours at room temperature. 
The solution was centrifuged at 6000rpm for 20 minutes, and the supernatant was 
removed. Ethanol was added to the centrifuge tube and the precipitate was re-dispersed 
by vortex and ultrasonication. The solution was then re-centrifuged at 6000rpm for 20 
minutes and the supernatant was discarded again. The precipitate was then re-dispersed in 
distilled water. 
 
2.4 Preparation of Ceria-coated Silica Nanoparticles 
 
The method was taken from Farooq, et al. (Farooq, Mohamed et al. 2014). Materials 
included: silica nanoparticles produced using SilC method, and ceria precursor from CeA. 
 
0.1g of the silica nanoparticles were dispersed in 30mL of distilled water and 3mL of cerium 
precursor solution. It was stirred for 30 minutes and the pH was adjusted to 9 by adding 
ammonium hydroxide. It was then stirred for 4 hours at 60C, in a silicon oil bath. It was 
then centrifuged at 6000rpm for 30 minutes, and washed with water and ethanol several 
times. 
2.5Size and morphology analysis of nanoparticles 
 
The size and morphology of the nanoparticles was assessed using both scanning electron 
microscopy (SEM) and transmission electron microscopy (TEM). Dilute nanoparticle 
solution (10 μL) was dried onto a clean silicon surface and imaged by field emission gun 
(FEG) SEM (Carl Zeiss Supra 40VP 
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FEG, Carl Zeiss,WelwynGarden City, Hertfordshire,UK); or placed on a mesh copper grid and 
imaged using the Tecnai 12 Biotwin TEM at 80 kV, at the University of Manchester. 
 
For SEM, the size of the nanoparticles were calculated using the SEM images (Figure 2), 
taking an average of 9 nanoparticle sizes. This sample size of 9 was chosen as it was the 
maximum amount of size measurements that can be taken electronically using the 
software provided. Manual measurements, although an option, would be less accurate.  
 
2.6Physicochemical characterisation of nanoparticles 
 
Physicochemical characterisation techniques include analysing hydrodynamic diameter and 
zeta potential, in both water and physiological salt solution (PSS). This was conducted using 
the Malvern ZetaSizer Nano ZS (Malvern, UK) which uses dynamic light scattering to 
analyse hydrodynamic diameter as well as being able to measure zeta potential.  
10µL of the original nanoparticle solution is diluted into 1mL of distilled water and added 
into the relevant cuvettes to take the measurements. A standard Malvern cuvette is used 
to measure the size by dynamic light scattering, and a capillary cell, which has electrodes 
on either side, is used to measure the zeta potential of the sample. 
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2.7 Calculation of nanoparticle number and dosage 
 
To determine concentration of stock nanoparticle solution, weight of a single nanoparticle 
was determined by rearranging the density equation: 
(1) 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑜𝑛𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑜𝑛𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
 
 
(2) 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑜𝑛𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =  𝑑𝑒𝑛𝑠𝑖𝑡𝑦 × 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑜𝑛𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 
 
Where the volume of one nanoparticle is calculated using the equation for the volume of a 
sphere, under the assumption that the nanoparticle is perfectly spherical, and the density is 
the assumed density of the material used, so in this instance, silica or cerium oxide. 
Once mass of one nanoparticle was calculated, 1mL of the stock solution of nanoparticles 
was dried and weighed. This mass was then divided by the mass of one nanoparticle 
calculated previously, and this determined how many particles per 1mL of stock solution 
there was.  
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2.8Results& Discussion 
2.8.1 Silica nanoparticles  
2.8.1.1 Size and morphology of dye-encapsulated silica nanoparticles using reverse 
microemulsion 
 
With nanoparticles, the ideal characteristics include: spherical nature, monodispersed, with 
all the nanoparticles being of the same size, and no aggregation or clumps seen. 
 
With the silica nanoparticles produced using the SilA and SilB method, the product proved 
undesirable as there was aggregation, as seen in Figure 4, when observed under electron 
microscopy and there was no clear distinction of individual nanoparticles. Because of this, 
another method was suggested as to produce a more desirable product that did not have 
aggregation and were more spherical in nature.Our aim is to produce nanoparticles that 
are able to be readily taken up by the vasculature with good physicochemical properties 
that allow for beneficial interaction with endothelial cells. 
 
Characterisation of the silica nanoparticles was not conducted on samples produced using 
the reverse microemulsion method (SilA and SilB method) as the product was deemed 
unsuitable for this project and its use was discontinued. 
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Figure 4SEM image of silica nanoparticles made using reverse microemulsion (SilA method) 
 
2.8.1.2 Size and morphology of non-dye-encapsulated silica nanoparticles  
 
Using a modified Stober method (SilC method), two batches of nanoparticles were 
produced following the same protocol, however, differences in size can be seen in Figure 
5A and 5B (approximately 120 nm and 70nm in diameter, respectively). These differences 
highlight the sensitive nature of nanoparticle production, one of the key issues in 
comparing nanoparticle research. 
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Figure 5SEM image of silica nanoparticles made using a modified Stober method (SilC method). A: SilC2; B: SilC3 
 
 
  
A 
B 
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2.8.1.3 Physicochemical characterisation of non- dye-encapsulated silica nanoparticles 
 
Physicochemical characterisation was conducted and the techniques adopted include 
analysing hydrodynamic diameter and zeta potential, in both water and physiological salt 
solution (PSS). This was conducted using the Malvern ZetaSizer Nano ZS (Malvern, UK) 
which uses dynamic light scattering to analyse hydrodynamic diameter as well as being able 
to measure zeta potential. Size of the nanoparticles were also calculated using the SEM 
images (Figure 2), taking an average of 9 nanoparticle sizes. This sample size of 9 was 
chosen as it was the maximum amount of size measurements that can be taken 
electronically using the software provided. Manual measurements, although an option, 
would be less accurate. 
The physicochemical characterisation for nanoparticles produced using the SilC method are 
listed in Table 2. Listed there is also the average size calculated from the SEM images, and a 
difference can be seen in the average size of the nanoparticles when comparing the two 
samples. 
The hydrodynamic diameter does differ between suspension in water and suspension in PSS. 
This is because there are ions present in the PSS that interact with the surface charge of the 
nanoparticle and therefore alter its hydrodynamic diameter.The diameter in PSS is therefore 
expected to be larger than in water, contrary to our findings. 
The zeta potential also changes when ions are present and this often leads to more unstable 
values being obtained for nanoparticles suspended in PSS. As mentioned previously, a zeta 
potential value of less than -25mV or greater than +25mV is considered 
stable(NanoComposix 2012). In Table 4, the values obtained from the nanoparticles 
suspended in water show high stability whereas the values obtained from the nanoparticles 
suspended in PSS show instability.  
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Table 4 Characterisation of silica nanoparticles produced by the modified Stober method (SilC method) 
 Silica nanoparticles 
(SilC2) 
Silica nanoparticles 
(SilC3) 
Average SEM 
diameter (nm) 
117.85 70.64 
Hydrodynamic 
diameter in 
water (nm) 
230.5 176.1 
Hydrodynamic 
diameter in PSS 
(nm) 
161.3 108.4 
Zeta Potential in 
water (mV) 
-104mV ± 17.4 -74.9mV ± 28.2  
Zeta Potential in 
PSS (mV) 
-22.6 -15.3 
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2.8.1.4 Size and morphology of dye-encapsulated silica nanoparticles  
 
The silica nanoparticles, produced using the A3 methodology, are shown in Figure 6 and 
can be seen to be of a spherical nature with some variations in morphology seen. They 
were monodispersed and did not show aggregation.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 TEM image of silica nanoparticles produced using A3 method 
 
The physicochemical characteristics for the silica nanoparticles (A3) are detailed in Table 5. 
Their hydrodynamic diameter seems to be smaller when suspended in PSS than in water. 
The zeta potential shows stability in water and instability in PSS as shown also in our 
synthesised silica nanoparticles. Sample A3 shows evidence of nucleation. This may be due 
to the length of time that the nanoparticles have been suspended in solution 
(approximately 1 year). 
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Table 5 Physicochemical characteristics of silica nanoparticles produced using the A3 method 
 
 
 
 
 
 
  
 Silica nanoparticles (A3) 
Average TEM size (nm) 98 
Hydrodynamic diameter in 
water (nm) 
141.83 
Hydrodynamic diameter in PSS 
(nm) 
124.1 
Zeta Potential in water (mV) -34.5 
Zeta Potential in PSS (mV) -12 
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2.8.2Ceria nanoparticles 
 
2.8.2.1 Size and morphology of ceria nanoparticles 
 
Previous studies suggest that ceria nanoparticles have a tendency to aggregate when 
synthesised(Rodea-Palomares, Boltes et al. 2011). This could possibly be due to the 
formation process of ceria nanoparticles where smaller nanoparticles cluster together to 
form aggregates, or it could be attributed to the physicochemical properties of the ceria 
nanoparticleswhich cause them to aggregate. In Figure 7, is the ceria nanoparticle sample 
made using the CeA method. This method produced ceria nanoparticles that contained 
aggregates over 200nm, and all varying in size and shape, although individual nanoparticles 
can also be visualised. Size and morphology was difficult to attain through the TEM images 
due to the individual nanoparticles being of such small size. Nanoparticles made using the 
CeA and CeB(seen in Figure 9A) method were deemed unsuitable, due to the high amount 
of aggregation. 
 
 
Figure 7TEM image of ceria nanoparticles produced using CeA Method 
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2.8.3 Post nanoparticle synthesis-steric stabilisation of ceria nanoparticles, using PVP, to look 
at effect of stabilisation on size, morphology and physicochemical characteristics 
 
2.8.3.1 Size and morphology of Sigma ceria nanoparticles (steric and non-steric stabilised) 
 
Steric stabilisation is a technique often used to help reduce aggregation by modifying or 
coating the surface of the nanoparticle. In doing so, it alters their physicochemical 
characteristics to allow fewer aggregates to form. 
 
Polymer coating using Polyvinylpyrrolidone (PVP) was investigated using ceriananoparticles 
purchased from Sigma Aldrich as well as ceria nanoparticles produced from the CeB method. 
These were chosen as they were the most aggregated of the ceria samples produced and it 
was unclear if PVP coating could be done after the production of the ceria nanoparticles.  
 
The ceria nanoparticles purchased from Sigma, although advertised as being less than 25nm, 
are shown to have particles around 50 and 100nm as well as those being under 25nm, as 
shown in Figure 8A. Along with the variation in size, there is also a variation in morphology, 
as some of the larger nanoparticles are of a square shape whereas the smaller nanoparticles 
are of a pentagonal or hexagonal shape. These nanoparticles were deemed unsuitable for 
use. 
When coated with PVP, there is aggregation of the smaller particles, which can be seen in 
Figure 8B. 
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Figure 8 TEM image of ceria nanoparticles purchased from Sigma Aldrich depicted in (A) and same sample of 
nanoparticles after PVP coating (B) 
 
  
A 
B 
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2.8.3.2 Physicochemical characteristics of sigma ceria nanoparticles (steric and non-steric 
stabilised) 
 
When looking at the physicochemical characerisation of the ceria nanoparticles purchased 
from Sigma, in Table 6, the hydrodynamic diameter increases dramatically when comparing 
the nanoparticles in water and in PSS. This is again understandable as the ions in PSS interact 
with the nanoparticles and contribute to the increase in hydrodynamic diameter. When PVP 
coating is added and the nanoparticles are suspended in water, there is an increase in 
hydrodynamic diameter. However, there seems to be an opposite effect when the 
nanoparticles are in PSS. The PVP coating reduces the hydrodyamic diameter of the 
nanoparticles when exposed to ions in the PSS. Looking at the zeta potential values, the PVP 
coating causes nanoparticle instability in both water and PSS. The reason for the lack of 
stabilisation in the Sigma ceria nanoparticles when coated with PVP remains unclear, but 
maybe related to insufficient coating of the NP surface. 
 
 
Table 6 Physicochemical characterisation of Sigma ceria nanoparticles with and without addition of PVP coat 
 Sigma ceria Nanoparticles 
(CeSig) 
PVP coated Sigma ceria 
nanoparticles (CeSigPVP) 
Hydrodynamic Diameter in 
water (nm) 
235.8 623.2 
Hydrodynamic diameter in 
PSS (nm) 
3.2x104 2040 
Zeta Potential in water (mV) -25±4.2 -0.401 
Zeta Potential in PSS (mV) -12.6 -1.46 
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2.8.3.3 Size and morphology of ceria (CeB) nanoparticles (steric and non-steric stabilised) 
 
The ceria nanoparticles produced using the CeB method, as previously mentioned, had high 
levels of aggregation, as seen in Figure 9A, and varied in size and morphology. Figure 9B 
shows the same CeB nanoparticle sample after coating with PVP. Smaller clusters of 
nanoparticles can be seen, of much smaller size than the aggregates seen in Figure 9A, that 
did not have the PVP coating. 
 
 
 
 
Figure 9 TEM image of ceria nanoparticles produced using CeB method depicted in (A) and the same sample of 
nanoparticles after PVP coating (B) 
A 
B 
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2.8.3.4 Physicochemical characteristics of ceria (CeB) nanoparticles (steric and non-steric 
stabilised nanoparticles) 
 
When looking at the physicochemical characterisation of these ceria nanoparticles (seen in 
Table 7), with and without the PVP coating, the PVP coating aids in reducing the 
hydrodynamic diameter both when the nanoparticles are suspended in water and PSS, as 
well as producing a more stable zeta potential. 
 
Table 7 Physicochemical characterisation of ceria nanoparticles produced using CeB method, with and without 
PVP coating 
 Ceria nanoparticles 
(CeB2) 
PVP coated ceria 
nanoparticles 
(CeB2PVP) 
Hydrodynamic diameter in water (nm) 1750 503.3 
Hydrodynamic diameter in PSS (nm) 2410 742 
Zeta Potential in water (mV) -0.242 -4.5 
Zeta Potential in PSS (mV) -1.56 -12.1 
 
2.8.4 Steric stabilisation amid ceria nanoparticle synthesis using PVP 
 
As well as applying a PVP coat to ceria nanoparticles, two methods were used that 
incorporated the PVP along with the starting materials for ceria nanoparticle production. 
This was due to the fact that, although PVP coating was able to bring about a slightly more 
stable suspension of nanoparticles, the nanoparticles were still highly aggregated. By 
introducing the PVP along with the starting materials, there is a high probability of coating 
individual nanoparticles as they are formed and before they adhere to one another.  
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2.8.4.1 Size and morphology of steric stabilised ceria (CeE) nanoparticles  
 
PVP coated ceria nanoparticles produced using the CeE method, show individual 
nanoparticles with pentagonal and hexagonal morphology, as seen in Figure10. Although 
there is agregation seen and the ceria nanoparticles retain their tendency to adhere to one 
another, the PVP coat has enabled the formation of individual nanoparticles. 
 
 
 
Figure 10 TEM image of PVP coated ceria nanoparticles produced using the CeE method 
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2.8.4.2 Physicochemical characteristics of steric stabilised ceria (CeE) nanoparticles 
 
When looking at the physicochemical characterisation of these nanoparticles, in Table 8, 
the hydrodynamic diameter values calculated show high levels of aggregation in both water 
and PSS. Despite the PVP coating allowing for individual nanoparticle formation, it did not 
contribute to reducing aggregation. The zeta potential values obtained for the 
nanoparticles suspended in water and PSS, indicate high instability and therefore would not 
be a desirable product to be used in this project.  
 
Table 8 Physicochemical characterisation of PVP coated ceria nanoparticles produced using CeE method 
 
 
 
 
 
 
 
 
2.8.4.3 Size and morphology of steric stabilised ceria (CeF) nanoparticles  
 
The CeF method was also used, which incorporated PVP into the starting materials. The 
difference with this method is that it did not have water as the solvent, instead it used 
ethylene glycol. This aids in producing individual nanoparticles of a more spherical nature, 
as demonstrated by Figure 11. Although variation in size is still seen (ranging from 
approximately 20nm to 50nm), the nanoparticles are much more defined in their shape. 
 PVP-coated ceria nanoparticles 
(CeE1) 
Hydrodynamic diameter in water (nm) 2908 
Hydrodynamic diameter in PSS (nm) 1172 
Zeta Potential in water (mV) -2.3 
Zeta Potential in PSS (mV) -1.78 
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Figure 11 TEM image showing ceria nanoparticles coated with PVP using CeF method 
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2.8.4.4 Physicochemical characteristics of steric stabilised (CeF) nanoparticles 
 
The physicochemical characterisation for the ceria nanoparticles made using the CeF 
method, are listed in Table 9. The hydrodynamic diameter shows high levels of aggregation 
when nanoparticles are suspended in PSS. The zeta potential for nanoparticles suspended 
in water and in PSS show instability, however, this may be due to a minute amount of 
ethylene glycol still present in the sample. 
 
 
Table 9Physicochemical characterisation of ceria nanoparticles produced using the CeF method 
 Ceria nanoparticles (CeF1) 
Hydrodynamic diameter in water (nm) 245.8 
Hydrodynamic diameter in PSS (nm) 569.3 
Zeta potential in water (mV) -15±5.82 
Zeta potential in PSS (mV) -5.32 
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2.8.5 Steric stabilisation amid ceria nanoparticle synthesis using dextran 
 
Dextran, a polymer made up of glucose molecules, has been used to coat nanoparticles and 
have been shown previously to be able to coat ceria nanoparticles without interfering with 
the antioxidant properties as well as enhanced uptake into endothelial cells(Perez, Asati et 
al. 2008). 
 
2.8.5.1 Size and morphology of steric stabilised  ceria (CeG) nanoparticles 
 
Dextran coated ceria nanoparticles were made using the CeG method. In this method, the 
dextran is incorporated along with the starting materials. In Figure 12, the dextran coated 
ceria nanoparticles are seen to be very small and clumped together. It is evident that the 
nanoparticles are too small to be analysed properly, therefore size and morphology could 
not be conducted on this sample. 
 
 
 
Figure 12SEM image of ceria nanoparticles coated with dextran using the CeG method 
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2.8.5.2 Physicochemical characteristics of steric stabilised ceria (CeG) nanoparticles 
 
The physicochemical characterisation for the dextran coated ceria nanoparticles are listed 
in Table 10. The hydrodynamic diameters collected show that aggregation is present and 
the zeta potential values do show slight instability in both water and in PSS. 
 
Table 10 showing the characterisation for the dextran coated nanoparticle sample (CeG1) 
 Ceria nanoparticles (CeG1) 
Hydrodynamic diameter in water (nm) 1032  
Hydrodynamic diameter in PSS (nm) 284.3 
Zeta Potential in water (mV) -18.6 
Zeta Potential in PSS (mV) -16.1 
 
 
2.8.6 Ceria-coated silica nanoparticles 
2.8.6.1 Size and morphology of ceria-coated silica nanoparticles 
 
These nanoparticles were produced using the ceria precursor produced from the CeA 
method and the silica nanoparticles produced from the SilC method, following the method 
outlined in (Oh, Lee et al. 2010). In Figure 13, it can be seen that the ceria nanoparticles are 
coated onto the silica nanoparticle surface. 
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Figure 13 shows the TEM image for the ceria coated silica nanoparticles 
 
2.8.6.2 Physicochemical characteristics of ceria-coated silica nanoparticles 
 
The physicochemical characterisation of the ceria coated silica nanoparticles are listed in 
Table 11. The hydrodynamic diameter, both when the nanoparticles are suspended in 
water and in PSS, show aggregation, although this may be due to the presence of ceria on 
the silica nanoparticles’ surface. The zeta potential values, in both water and PSS, show 
instability. 
Table 11 shows the characterisation for the ceria coated silica nanoparticle (SilC3Ce1) 
 Ceria coated silica 
nanoparticles (SilC3Ce1) 
Hydrodynamic diameter in water (nm) 8042 
Hydrodynamic diameter in PSS (nm)  367.5 
Zeta Potential in water (mV) -14.1 
Zeta Potential in PSS (mV) -5.45 
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3. Objective 2: Vascular Functional Studies 
 
3.1 Methodology 
 
3.1.1. Organ bath studies 
 
C57/BLACK 6 mice were used for this project, of two age groups:7 young mice aged 
between 10-19 weeks, and7 aged mice aged between 74-106 weeks. Not all data is 
included for all of these animals as some were used to optimise the equipment 
used.Animals were sacrificed by cervical dislocation of the neck, in accordance with 
institutional guidelines and the Scientific procedures act, 1986 (Schedule 1) and ethics 
approval. The heart and lungs, along with the connecting vessels were removed enblock 
and the aorta was then dissected away and any fat removed. Aortas were cut into aortic 
rings of 3mm in length. These aortic rings were then mounted onto a calibrated organ bath 
system, as shown in Figure 14. Physiological conditions were set, by immersing in 
oxygenated (95% oxygen; 5% CO2) physiological salt solution [PSS], of the following 
composition: 119 NaCl, 4.7 KCl, 1.2 MgSO4·7H2O, 25 NaHCO3, 1.17 KHPO4, 0.03 K2EDTA, 5.5 
glucose, and 1.6 CaCl2·2H2O; pH 
7.4.Solutions were maintained at  35˚C. 
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Figure 14Schematic showing the organ bath system(taken from Akbar, et al. 2011) 
 
The organ bath system was initially calibrated as detailed in the appendix. Once mounted 
into the organ bath system, aortic rings from both young and aged groups underwent the 
same protocol, which is outlined in Figure 15.Constrictor responses were examined using 
high potassium PSS (KPSS) solution and Phenylephrine (Phe). Acetylcholine was used to 
assess endothelial-dependent dilation, whilst sodium nitroprusside was used to assess 
endothelial-independent dilation. 
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Figure 15 Schematic showing the protocol for the organ bath experiments 
Young Mice Aged Mice 
Acetylcholine Cumulative Dose Response (Pre-incubation) 
Concentrations used: 1x10-9, 1x10-8, 1x10-7, 1x10-6, 1x10-5, 1x10-4, 1x10-3 
Incubation for 30 minutes 
Control Group: Incubation in PSS 
Nanoparticle Group: Silica (A3), silica (SilC3), and ceria-coated silica 
(SilC3Ce1) at  
1.31x1011 particles/mL 
Acetylcholine Cumulative Dose Response (Post-incubation) 
Concentrations used: 1x10-9, 1x10-8, 1x10-7, 1x10-6, 1x10-5, 1x10-4, 1x10-3 
Sodium Nitroprusside Cumulative Dose Response (Post-incubation) 
Concentrations used: 1x10-9, 1x10-8, 1x10-7, 1x10-6, 1x10-5, 1x10-4, 1x10-3 
2 x KPSS Constriction  
Phenylephrine constriction  
Phenylephrine constriction  
KPSS Constriction 
Phenylephrine constriction  
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For the control group, vessels were incubated in PSS over 30 minutes and reconstricted. The 
Ach and SNP cumulative dose responses were repeated. The vessel again constricted and an 
SNP cumulative dose response carried out. At the end of the experiment, the vessel was 
washed in PSS.  
To assess the influence of nanoparticles on constrictor and dilator responses, vessels were 
incubated in any one of the following nanoparticles for 30 minutes, washed, then reassessed 
using cumulative doses of Ach, and SNP: 
For all the nanoparticles above vessel incubation was made to a final dosage of 1.31 x 1011 
NP/ml in a 15mL organ bath. The amount added was calculated using the C1V1=C2V2 
equation, as the concentration of the stock solution of nanoparticles was already calculated, 
as previously mentioned. 
 
3.1.2 Interpreting raw data from organ bath studies 
 
The raw data, known as traces, consist of tension values obtained through contraction and 
dilation of the aortic ring. From these tension values, the percentage dilation from each 
cumulative dose response was calculated and a response curve was generated. Percentage 
dilation was calculated using the following formula: 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑑𝑖𝑙𝑎𝑡𝑖𝑜𝑛 =  
𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑡𝑒𝑛𝑠𝑖𝑜𝑛 𝑑𝑢𝑟𝑖𝑛𝑔 𝑑𝑖𝑙𝑎𝑡𝑖𝑜𝑛
𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑡𝑒𝑛𝑠𝑖𝑜𝑛
× 100% 
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Two chemicals were used to induce endothelial dilation in the aortic rings. Acetylcholine 
(Ach)was used to induce endothelial-dependent dilation, and sodium nitroprusside 
(SNP)was used to induce endothelial-independent dilation. 
 
3.1.3 Tissue fixation and TEM 
 
At the end of an experiment, some vessels were immediately fixed in 2.5% glutaraldehyde 
in 0.1Msodium cacodylate buffer, pH 7.3 over 2 H at 22◦C, then kept in cacodylate buffer 
until processed for transmission electron microscopy (TEM) at the university of manchester 
(UoM). Ultrathin 70 nm sections were cut with Leica “Ultracut S” ultramicrotome and 
placed on copper grids by the technical staff. The grids were observed (using the Tecnai 12 
Biotwin TEM at 80 kV) at UoM. 
 
3.1.4 Statistical analysis for organ bath data 
 
Data are given as mean ± standard error of mean with n representing 
the number of rats/vessels. Dilator responses are expressed 
as percent relaxation. 
For analysing the repeatability of the vasodilator responses, a paired t-test was conducted, 
as it was an analysis before and after an incubation, using the same vessel. This statistical 
analysis was conducted using IBM SPSS software. 
For analysing the nanoparticle influence on vasodilator responses, a one-way ANOVA was 
conducted with Bonferroni and Tukey post-hoc tests. This was chosen as it was a 
comparison of more than two experimental conditions and was not conducted on the same 
vessel. 
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3.2 Results& Discussion 
 
3.2.1. Constrictor responses in young mice 
 
Preliminary results were conducted to establish the resting tension necessary to achieve 
the highest constrictor response, using Phe. Tensions of 0.1; 0.2; 0.3; 0.4; and 0.5 g tensions 
were tested, the data for which, can be found in the appendix. Vessels set up at 0.4g 
tension achieved the highest Phe constrictor response. Therefore, vessels were set up at 
0.4g tension, as the resting tension of the vessel. 
 
During the experiment protocol, vessels were initially induced to contract using 15mL 
ofKPSS. This established the viability of the vessels. This step was repeated 2 times. Vessels 
reaching less than 0.16 g tension were discarded.  Vessels were subsequently constricted 
using Phe at a final bath concentration of 1mM before the cumulative dose response for 
Ach is conducted.  The average tension values for responses to KPSS and Phe are given in 
Table 12 below.  
 
Table 12 Average tension achieved using high potassium PSS and phenylephrine in young mice 
 Average tension achieved (g)± SD 
High potassium PSS 0.33 ± 0.10 
Phenylephrine 0.25 ± 0.14 
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3.2.2 Constrictor responses in aged mice 
 
Vessels from the aged mice were also induced to contract using a high potassium PSS, and 
a 1x10-3dose of phenylephrine. The average tension achieved in the initial 
contraction,before the acetylcholine dose response (pre incubation), can be seen in Table 
13. 
 
Table 13 Average tension achieved using high potassium PSS and phenylephrine in aged mice 
 Average tension achieved (g) ± SD 
High potassium PSS 0.58 ± 0.38 
Phenylephrine 0.48 ± 0.18 
 
 
3.2.3 Repeatability of acetylcholine dilator responses in young mice 
 
All vessels dilate when acetylcholine is present, and it dilates in a dose-dependent manner. 
It is this dose response that is used in the comparisons. Assessing the repeatability of the 
acetylcholine dilator response before and after a PSS incubation enables us to investigate if 
the responses can be directly compared. In Figure 16, it can be seen that the acetylcholine 
response post incubation is significantly lower than the response achieved pre incubation 
(p<0.01, at 0.1µM to 1mM). Due to this, only post-incubation responses were compared 
when analysing nanoparticle influence on vasodilator responses. 
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Figure 16 Percentage dilation during an acetylcholine dose response before (n=10) and after (n=4) incubation in 
PSS. *p<0.05; **p<0.01. 
 
3.2.4The influence of age on acetylcholine dilator function 
 
When looking at the acetylcholine dose response achieved from the young mice, in Figure 
17, there can be seen that, with each increasing dose there is an increase in the dilation of 
the aortic ring. This dilation peaks at 45%, when the concentration of the acetylcholine 
reaches 1x10-4M and begins to have a slight contractile effect at concentration 1x10-3M. 
The acetylcholine dose response achieved in aged mice, also seen in Figure 14, also show 
an increase in dilation of the aortic ring with each increasing dose. The dilation peaks at 
almost 50% when the concentration reaches 1x10-6M, and remains relatively steady for 
subsequent concentrations. 
When comparing the responses between the young and the aged, using statistical analysis, 
there was found to be no significant difference.  
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Figure 17 Comparison of the percentage dilation during an acetylcholine dose response in young(n=4)  and in 
aged (n=3) 
 
3.2.5The influence of nanoparticle incubation on acetylcholine dilator response in young mice 
 
After incubation in nanoparticles, the aortic rings from young mice underwent another 
acetylcholine dose response, seen in Figure 18. Although the acetylcholine response shows 
a similar trend after each of the nanoparticle incubations, the ceria-coated silica 
nanoparticle incubation caused an increased dilator response than that seen after the silica 
nanoparticle incubation or the PSS incubation. Statistical analysis shows that the ceria-
coated silica nanoparticle incubation caused a significant increase in dilator response at the 
concentration 1x10-7M when compared to the acetylcholine response after both the silica 
nanoparticle and PSS incubation( p< 0.05). There was also no statistical difference seen 
when comparing the acetylcholine dilator response after silica nanoparticle incubation and 
PSS incubation. 
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Figure 18 Percentage dilation during an acetylcholine dose response after incubation with either PSS (n=6), silica 
nanoparticles (A3) (n=4) or ceria-coated silica (n=3) 
 
3.2.6 The influence of nanoparticle incubation on sodium nitroprusside dilator response in 
young mice 
 
In Figure 19, it can be seen that the sodium nitroprusside response causes an increase in 
dilation percentage at each concentration, regardless of whether the aortic ring was 
incubated in silica or ceria-coated silica nanoparticles, or in PSS. The sodium nitroprusside 
responses after incubation with nanoparticles, both silica and ceria-coated silica, showed 
no statistically significant difference to the controls. 
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Figure 19 Percentage dilation during a sodium nitroprusside dose response after incubation with either PSS 
(n=6), silica nanoparticles (A3) (n=4) or ceria-coated silica (n=3) 
 
3.2.7 The influence of nanoparticle incubation on acetylcholine dilator response in old mice 
 
After incubation in nanoparticles, another acetylcholine dose response was conducted, 
seen in Figure 20. The acetylcholine dose response after incubation in silica (SilC3) and 
ceria-coated silica, show no difference when compared to the response after incubation in 
PSS. However, there is a detrimental effect to the acetylcholine dose response after 
incubation in silica (A3) nanoparticles when compared to the acetylcholine dose response 
after incubation with PSS. This was, however, also not found to be statistically significant.   
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Figure 20 Percentage dilation during an acetylcholine dose response, in aged mice, post-incubation in either PSS 
(n=4), silica nanoparticles (Ali’s A3) (n=2), silica nanoparticles (SilC3) (n=3), or ceria coated silica nanoparticles 
(n=3) 
 
3.2.8 The influence of nanoparticle incubation on sodium nitroprusside dilator response in old 
mice 
 
In Figure 21, it can be seen that the sodium nitroprusside response causes an increase in 
dilation percentage at each concentration, regardless of incubation. The sodium 
nitroprusside responses after incubation with nanoparticles, silica and ceria-coated silica, 
show no statistically significant difference to the controls. 
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
-9.00 -8.00 -7.00 -6.00 -5.00 -4.00 -3.00
P
er
ce
n
ta
ge
 D
ila
ti
o
n
 (
%
)
Log10 Concentration of Acetylcholine (M)
Acetylcholine Dose Response in Aged Mice
PSS Silica (A3) Silica (SilC3) Ceria-coated Silica (SilC3Ce1)
71 
 
 
Figure 21 Percentage dilation during a sodium nitroprusside dose response post-incubation in either PSS (n=4), 
silica nanoparticles (Ali’s A3) (n=2), silica nanoparticles (SilC3) (n=3), or ceria-coated silica nanoparticles (n=3) 
3.2.9 Evaluation of uptake of nanoparticles using TEM 
 
After fixation and processing, vessel tissue was cross sectioned and viewed using TEM. 
Difficulty in obtaining an intact endothelium meant analysis of uptake was unsuccessful, 
however some images of nanoparticles within the processed tissue can be seen in Figure 
22. 
 
Figure 22 TEM image of silica (A3) nanoparticles surrounding an endothelial cell 
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4. General Discussion and Conclusion 
4.1 Nanoparticle synthesis and characterisation 
 
A number of methodologies were examined in the present study to synthesise 
monodispersed and spherical nanoparticles, of 2 different material compositions: Silica (3 
methods) and Ceria (6 methods). These were compared to other nanoparticles, either 
already available in our lab (A3 Silica nanoparticles), or commercially available (Ceria 
nanoparticles from Sigma). Additionally, some of the silica nanoparticles were also coated 
in ceria, to produce ‘ceria-coated silica nanoparticles’.  
The nanoparticles synthesised showed a variation in physicochemical properties and 
therefore, those selected for the present study had to be comparable to one another, 
which is why the ceria-coated silica and silica (SilC3) nanoparticles were used for further 
vessel physiology testing. Comparisons were made to silica nanoparticles made previously 
in our lab (A3). 
The present study demonstrates the successful synthesis of ceria nanoparticles of 20-50 nm 
in size (CeF1), by incorporation of PVP polymer into the starting material and using 
ethylene glycol instead of water as the solvent material. This overcame the high level of 
aggregation seen when using other methods of synthesis. However, use of PVP can prevent 
nanoparticle uptake into endothelial cells and tissues, as it has previously been used to 
enhance the circulation time of nanoparticles in blood(Duan and Li 2013). Although dextran 
(used to enhance nanoparticle uptake) was used as an alternative coating method to 
improve steric stability of the ceria nanoparticles, aggregation remained a problem. This 
may be due to the very small size of the ceria nanoparticles …. 
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Ceria coating of silica nanoparticles was achieved in the present study using the method 
previously described by Farooq, et al. 2014, who also looked at the restoration of dilator 
responses using ceria. Coating was confirmed by TEM analysis . Although most of the 
surface was covered, isolated aggregates of ceria nanoparticles alone was also seen. This 
may have contributed to the increased values of hydrodynamic diameter. 
 
4.2 Do aged mice show compromised dilator responses to acetylcholine? 
 
Aortic vessels from young and aged mice were isolated and maintained under conditions 
that mimic the physiological state. All vessels constricted to high potassium solution, 
demonstrating their viability.  The results in the present study have found that there is no 
compromised endothelial dependent (Ach) dilator responses seen in aged mice when 
compared to young mice. The acetylcholine dose response achieved in young and aged 
mice, show no statistically significant difference. This was unexpected, since reduced 
dilator responses in aged vessels has previously been documented, due to reduced 
availability of nitric oxide(Yang, Huang et al. 2009). However, the present results are 
supported by the finding in our lab, that femoral arteries from the same aged mice, also 
showed similar dilator responses to those from young mice (Diaz et al, in preparation). The 
reason for this may be due to the possibility, that reduced nitric oxide levels may be 
compensated by other vasodilators such as EDHFs. 
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4.3 Do silica nanoparticles compromise dilator responses in young or aged mice? 
 
Incubation of vessels in silica and ceria-coated silica nanoparticles had no overall effect on 
constrictor responses [Phe]. All vessels, from young and aged mice, demonstrated a dose 
dependent increase in endothelial independent dilator responses [SNP], after nanoparticle 
incubation, demonstrating that smooth muscle cell sensitivity was unaffected by the 
nanoparticles.  However, changes were observed in endothelial dependent (Ach) dilation, 
after nanoparticle incubation, as follows:  In young mice, the silica nanoparticles (A3) 
caused no overall change in dilator responses compared to the controls (figure 15) whereas 
in the aged mice, the same A3 silica nanoparticles caused a reduction in dilator responses 
(figure 17). Another type of silica nanoparticle (C3), however, showed no reduction in 
dilator responses in aged mice, indicating that the physicochemical characteristics can 
impact the biocompatibility. The reason why the A3 silica nanoparticles had a reduced 
effect on dilator capacity of old but not aged vessels, may relate also to the fact that the 
types of mediators released in aged vessels may be different from young vessels. A3 silica 
nanoparticles were dye encapsulated and we have demonstrated evidence in our lab that 
this can generate reactive oxygen species, thus interfering with nitric oxide release and 
leading to reduced dilation (Farooq et al, 2013). This is supported by the fact that in the 
present study, C3 silica nanoparticles (which do not contain the dye) did not reduce the 
dilator component in the aged vessels.  
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4.4 Can adding a ceria coat, improve dilator responses? 
 
In young mice, there is an improvement in dilator responses seen after incubation with 
ceria-coated silica nanoparticles, however, no improvement is seen in the aged mice. This 
result is promising, but further studies are required in order to compare the ceria-coated 
silica nanoparticles with the bare silica nanoparticles without the ceria coat (C3). The 
present study confirms previous findings by Farooq et al (2014).  They used aortic vessels 
from young male Wistar rats and demonstrated that incubation of vessels in silica 
nanoparticles alone caused a significant reduction in endothelial dependent dilation (Ach). 
Incubation in ceria coated silica nanoparticles, led to a significant improvement in dilation 
(Farooq et al, 2014). The authors suggest that as ceria is available in 2 oxidation states, it 
can behave as a reactive oxygen species scavenger, scavenging any ROS generated by the 
surface of the silica nanoparticles, which may have led to the original reduction in dilation 
(Farooq et al, 2014). 
 
The additional finding, in the present study, is that ceria coating of silica nanoparticles does 
not improve dilation in the aortic vessels from aged mice. This is expected, since the 
uncoated silica nanoparticles (C3) had no detrimental effect on endothelial dependent 
dilator responses and the dilator component in aged vessels is uncompromised, compared 
to that in young vessels. 
 
4.5.Future work and study limitations 
 
From the current work, it has been shown that, firstly, the ceria-coated silica nanoparticles 
has an improved dilatory effect on the young mouse aorta, whereas silica nanoparticles do 
not have a statistically significantreduced effect on dilation. The future workcan investigate 
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the underlying mechanisms that are responsible for the improved dilation after incubation 
with ceria-coated silica nanoparticles. Secondly, ceria-coated silica nanoparticles do not 
improve dilation in aged aortic vessels while uncoated silica nanoparticles (C3) had no 
detrimental effect on dilator responses. This is expected since the dilator component in 
aged vessels is similar to that in young vessels. 
 
4.5.1Further characterisation of silica and ceria-coated silica nanoparticles 
 
Additional characterisation techniques will be necessary on the silica and ceria-coated silica 
nanoparticles. These include: 
 
1. Determining the concentration of oxygen vacancies using Raman spectroscopy 
using the calculations outlined in (Thanneeru 2004). It has been shown that ceria 
nanoparticles have an increased concentration of oxygen vacancies, which are 
responsible for their high redox potential and antioxidant properties. The Raman 
spectroscopy will allow the calculation of the oxygen vacancy concentration and 
confirm an increased concentration in the ceria-coated silica nanoparticles. 
 
2. Establishing the oxidative capacity of silica and ceria-coated silica nanoparticles in 
various solutions (water, PSS and cell culture medium) using a DTT assay following 
the protocol outlines in (Koike and Kobayashi 2006). There are two objectives from 
this technique: (1) To confirm that ceria-coated silica nanoparticles have an 
increased antioxidant capacity when compared to silica nanoparticles and (2) that 
the oxidative capacities of the nanoparticles remains the same in the different 
suspensions (water, PSS and in cell culture medium) 
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4. 5.2. Nanoparticle influence on vascular function and deduction of vasodilatory 
mechanisms 
 
The findings from the present study were based on limited numbers of experiments, due to 
the limited availability of tissue, especially that from aged mice. It will be important to 
confirm findings on the influence of nanoparticles on vasodilator function and the 
vasodilatory mechanisms that are responsible. This  can be  done by Increasing data from 
organ bath studies following the protocol outlined in this report, using young mice, to 
validate the current findings. For example, Silica (SilC3) nanoparticle incubation and 
assessment of vasodilation response (n=4 need to be conducted); Ceria-coated silica 
nanoparticle incubation and assessment of vasodilation response (n=3 need to be 
conducted). 
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4.5.3 Deduction of vasodilatory mechanisms in mouse aorta and the influence of 
nanoparticle incubation on those mechanisms 
 
1. Establishing the vasodilatory component in mouse aorta using inhibition studies: 
 
a. Using L-NG-nitro-L-arginine (LNNA) to inhibit the nitric oxide (NO) pathway 
to assess the change in vasodilation response and effect of nanoparticle 
incubation 
 
b. Using indomethacin to inhibit the prostacyclin pathway to assess the 
change in vasodilation response and effect of nanoparticle incubation 
 
c. Using apamin and TRAM-34 to inhibit potassium channels (small 
conductance calcium activated and intermediate conductance calcium 
activated potassium channels respectively) that interfere with the 
endothelial derived hyperpolarising factor (EDHF) pathway 
 
2. Establishing the mechanism of ceria-coated nanoparticle-induced altered dilation 
using inhibition studies by co-incubating a vasodilator inhibitor with ceria-coated 
nanoparticles and decipher which mechanism of vasodilation is being acted upon 
by the ceria-coated silica nanoparticles  
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4.5.4Comparison of structural features in young and old mice using histology sections 
 
To compare the young and old mice vessel structure, histology techniques will be used 
including: 
 
1. Embedding aortic vessel rings into paraffin after first fixing with paraformaldehyde 
and then dehydration using industrial methylated spirit and xylene. Sectioning and 
staining will be conducted to be able to distinguish the structural components and 
to look at differences 
2. Embedding aortic vessel rings into OCTwhich is then frozen immediately using 
liquid nitrogen.Sections will then be taken and hydroethidine dye will be applied 
topically. Once sample was ready to be viewed, under fluorescence microscopy 
(Alexander, Brosnan et al. 2000) 
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4.5.5.Influence of silica and ceria-coated silica nanoparticles on cell viability and vasodilator 
function using mouse aortic endothelial cells  
 
In order to elucidate the mechanisms behind the improved vasodilation response seen in 
young mice after incubation with ceria-coated silica nanoparticles, in vitro work will be 
necessary to look at vasodilatory mechanisms responsible for this effect. This includes: 
1. Obtaining mouse aortic endothelial cells fromCellBiologics Inc, USA (Cat #: C57-
6052) so that results are comparable to the vascular functional studies conducted 
on mice 
2. Ensuring cells are viable by using the MTT assay, a colorimetric assay, which 
assesses metabolic activity of cells and therefore determines viability 
3. Investigating expression of enzymes involved in the various vasodilatory pathways 
will be quantified using Western Blotting  
4. Effect of ceria-coated silica on ROS production will be assessed using carboxy-
H2DCFDA, outlined in (Wu and Yotnda 2011). The is a fluorometric assay which can 
be analysed using flow cytometry, a fluorescence plate reader, or flow cytometry 
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6. APPENDIX 
 
6.1. Publications arising from the project 
 
Tye, E., Shukur, A., Farooq, A., Wilkinson, F., Alexander, Y., Whitehead, D., and Azzawi, M. 
(2015) ‘A comparison of silica nanoparticle uptake and their effects on young and aged 
murine arterial function, ex vivo.’ Microcirculation, Vol.22, pp. 753-781 
 
6.2. Chemical characterisation of nanoparticles 
6.2.1. Hydrodynamic diameter 
 
Listed below are the outputs measuring hydrodynamic diameter of various nanoparticles 
used in this present study. Figure 23 shows hydrodynamic diameter in silica (C3) 
nanoparticles and Figure 24 shows the hydrodynamic diameter of ceria-coated silica 
nanoparticles (SilC3Ce1). 
 
 
Figure 23 Hydrodynamic diameter of silica nanoparticles (SilC3) in water, as measured using DLS 
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Figure 24 Hydrodynamic diameter of ceria-coated silica nanoparticles (SilC3Ce1), as measured using DLS 
 
6.3. Calibration of organ bath system 
 
Before each organ bath experiment was conducted, the system was calibrated by adding 
two 1g weights onto the transducer and adjusting the readings given on the LabChart 
software to read 1g and 2g when one or two weight, respectively, were added. Once these 
weights were removed, the reading would be at ‘0’ and then the experiment followed as 
previously mentioned. 
 
6.4 Preliminary resting tension data 
 
Table 14 KPSS and phenylephrine response after various resting tensions were applied to the vessel 
Resting Tension (g) KPSS response achieved (g) Phenylephrine response 
achieved (g) 
0.05 0.010 0.02 
0.10 0.035 0.1 
0.20 0.045 0.00 
0.30 0.015 0.00 
0.40 0.040 0.00 
0.50 0.025 0.00 
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Table 15 Acetylcholine (at 10-4M and 10-3M) response after various resting tensions were applied to the vessel 
Resting Tension (g) Tension achieved at Ach 
10-4 M 
Tension achieved at Ach 
10-3 M 
0.1 0.00 0.00 
0.2 0.03 0.04 
0.3 0.05 0.05 
0.4 0.03 0.05 
0.5 0.02 0.04 
 
Based on both the KPSS, phenylephrine and acetylcholine responses, 0.4g resting tension 
was used for this study. 
6.6. COSHH forms 
 
Below are attached the COSHH and risk assessment forms for this study. 
